Axsome Therapeutics (AXSM) vs Kiniksa Pharmaceuticals International (KNSA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Kiniksa Pharmaceuticals International (KNSA) has outperformed Axsome Therapeutics (AXSM) over the past year, gaining 125.8% versus a loss of 13.4%. Over five years, KNSA leads with a +706.0% price change compared with +250.4% for AXSM. Kiniksa Pharmaceuticals International is the larger company by market cap ($7.38 billion vs $6.80 billion), about 1.1 times the size, while Axsome Therapeutics is growing revenue faster (+65.5% vs +60.1%).
On valuation, Axsome Therapeutics trades at a lower forward P/E (35.5x vs 45.9x for Kiniksa Pharmaceuticals International). Kiniksa Pharmaceuticals International converts more of its revenue into profit, with a net margin of 8.7% versus -28.7%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AXSM | KNSA |
|---|---|---|
| Share price | $129.36 | $93.90 |
| Market cap | $6.80B | $7.38B |
| 1-day change | -4.66% | +0.38% |
| YTD return | -29.17% | +127.62% |
| 1-year return | -13.44% | +125.82% |
| 5-year return | +250.38% | +705.97% |
| P/E ratio (TTM) | — | 71.13 |
| Forward P/E | 35.47 | 45.91 |
| EPS (TTM) | $-3.03 | $1.32 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $638.50M | $677.56M |
| Revenue growth (YoY) | +65.55% | +60.09% |
| Net income (latest FY) | $-183.17M | $59.01M |
| Gross margin | 92.56% | 88.54% |
| Operating margin | -26.12% | 11.40% |
| Net margin | -28.69% | 8.71% |
| 52-week high | $260.19 | $99.31 |
| 52-week low | $123.00 | $37.02 |
| Distance from 52-week high | -50.28% | -5.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +104.56% | +18.82% |
| Average volume | 865.33K | 664.53K |
| Shares outstanding | 52.60M | 48.84M |
| Employees | 1,390 | 366 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- KNSA has outperformed AXSM by 139.3 percentage points over the past year.
- Kiniksa Pharmaceuticals International is more profitable, keeping 8.7 cents of every revenue dollar as net income versus -28.7 cents for Axsome Therapeutics.
- Axsome Therapeutics grew revenue faster in its latest fiscal year (+65.55% vs +60.09%).
About Axsome Therapeutics
AXSM stock →Axsome Therapeutics, Inc., a biopharmaceutical company, develops and delivers novel therapies for the management of central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist, sigma-1 receptor agonist, aminoketone, and CYP2D6 inhibitor indicated for the treatment of major depressive disorder in adults; Sunosi (solriamfetol), a dopamine and norepinephrine reuptake inhibitor, trace amine-associated receptor 1 agonist, and 5-HT1A agonist indicated for the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea; and Symbravo (MoSEIC meloxicam rizatriptan), or AXS-07, a rapidly absorbed, multi-mechanistic, selective COX-2 inhibitor, and 5-HT1B/1D agonist indicated for the acute treatment of migraine with or without aura.
Health Care · Biotechnology: Pharmaceutical Preparations · 1,390 employees
About Kiniksa Pharmaceuticals International
KNSA stock →Kiniksa Pharmaceuticals International, plc, a biopharmaceutical company, develops and commercializes medical therapies in the United States, the United Kingdom, and internationally. The company offers ARCALYST, an interleukin-1alpha and 1beta cytokine trap for the treatment of recurrent pericarditis, a chronic autoinflammatory cardiovascular disease and cardiac sarcoidosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 366 employees
AXSM vs KNSA FAQ
Which is bigger, Axsome Therapeutics or Kiniksa Pharmaceuticals International?
Kiniksa Pharmaceuticals International (KNSA) is larger, with a market capitalization of $7.38B compared with $6.80B for Axsome Therapeutics (AXSM).
Which stock has performed better over the past year, AXSM or KNSA?
KNSA returned +125.82% over the past 12 months, compared with -13.44% for AXSM (price return, excluding dividends). Past performance does not predict future results.
Are Axsome Therapeutics and Kiniksa Pharmaceuticals International in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.